Chaoju Eye Care (2219.HK): A $230M Chinese Eye-Hospital Chain at 1.6x EV/EBITDA Where Cash Almost Equals the Market Cap

Down roughly 76 percent from its 2021 Hong Kong IPO, sitting on cash and structured deposits worth nearly its entire market cap. That is the headline shape of $2219.HK, Chaoju Eye Care Holdings (朝聚眼科). A Chinese chain of 31 eye hospitals, roughly $230 million market cap, ~9.5 percent dividend yield, buying back stock that actually cancels. At ~1.6x EV/EBITDA, the operating business is almost free.

The factor framework reads it as Strong Buy at StockRank 99 of 100. The market has spent four years pricing it like a value trap. Both of those things can be true at once, and this post is an attempt to lay out which one you are actually buying.

The Lifecycle Insight: One Patient, Three Transactions

The first thing to get right on Chaoju is the structure of demand for what it sells, because it is far cleaner than the average healthcare consumer.

Our eyes fail in a predictable order across a human lifetime. Myopic children need lens control around age 8 to 12, often via overnight orthokeratology (ortho-k) lenses. Young adults with the means and the vanity to do so pay cash for refractive laser surgery to lose their glasses in their 20s and 30s, increasingly via the higher-margin SMILE Pro procedure. The elderly need cataract work in their 60s and 70s, much of which has historically been reimbursed by the Chinese state.

Chaoju sells to all three stages. One patient, three transactions across decades. The 12-year-old fitted for overnight ortho-k lenses returns at 30 for SMILE laser, and again at 65 for a cataract intraocular lens. The clinic remembers the family.

Demand at this shape is not cyclical in any normal sense. It is demographic. Every cohort ages into the next procedure. The denominator is the entire Chinese population, and the conversion across cohorts is governed by biology rather than by economic mood.

The Moat in Hamilton Helmer's Vocabulary

The temptation when looking at an eye-hospital chain is to assume the moat is the equipment. It is not. Anyone with capital can buy a Zeiss laser platform. The moat is what capital cannot rush.

Two of the seven Powers in Hamilton Helmer's framework apply to Chaoju and reinforce each other:

• Cornered Resource. Class 3A hospital licences in China are not granted on demand. They are awarded scarcely and earned through years of clinical outcomes, staff credentials and capital investment. Each Chaoju 3A hospital is a regulatory asset a new entrant cannot replicate inside one capex cycle. The familiar senior surgeons attached to those facilities are the other half of the resource: the patient remembers the surgeon's name as much as the clinic's.
• Branding. Nobody shops on price for someone cutting into their eye. The decision is dominated by trust signals: brand reputation, surgeon credentials, hospital tier, word of mouth inside the family. The price elasticity that governs most consumer categories simply does not apply to the discretionary refractive segment in the same way. The Chaoju brand, built over years across northern China, lowers the cost of acquiring each next patient.

We covered the broader category of these stacked moats in our explainer on what an economic moat actually is. The closest structural analogue in the catalog is Frontken (0128.KL): a different industry, but the same shape of moat where certification, regulator-graded process trust, and customer-relationship history all combine into something a well-funded competitor cannot meaningfully erode in a single capex cycle.

Why Sales Dipped Roughly 3 Percent in 2025

The bull case has to honour the operating reality of the last 18 months. Sales dipped roughly 3 percent in 2025, and there are two distinct reasons.

The first is a weak Chinese consumer. Refractive surgery is discretionary, cash-pay, and at the upper end of middle-class spending priorities. When the household balance sheet feels stretched, the laser appointment gets pushed back six or twelve months. That is happening across the elective-procedure category in China right now, and Chaoju is not exempt.

The second is a state policy headwind on the cataract side. Reimbursed cataract surgery prices were cut by regulators as part of broader medical-cost containment, which compresses Chaoju's margin per state-funded cataract case even when volume holds.

The path back, management argues, runs through product mix. The higher-margin SMILE Pro laser procedure is being pushed aggressively into the refractive segment as the consumer-discretionary side of the business stabilises. The cataract side migrates toward higher-end multifocal intraocular lenses that the wealthier patient pays for above the state reimbursement floor. Mix improvement is doing the work that volume cannot do in a softer demand environment.

The Capital Return Surprise

Here is the part of the Chaoju story that most casual observers miss. As 2025 profit slipped, the declared FY2025 final dividend more than doubled.

Payout ratio at roughly 90 percent. Trailing yield at roughly 9.5 percent. Funded entirely by operating cash flow and a net-cash balance sheet, not by leverage. Buybacks layered on top, and the buybacks are the kind that actually cancel shares rather than warehouse them for re-issuance.

A controlling shareholder authorising a dividend doubling in a year when reported earnings fell is a deliberate capital-allocation signal. The most natural read is that management views the cash balance as significantly in excess of what the operating business needs, and is willing to return it aggressively rather than chase acquisitions for the sake of deploying it. That is the stance shareholders generally want from management of a cash-rich, slow-growth franchise.

"At ~1.6x EV/EBITDA, the business is almost free."

Two Growth Levers: Consolidation and the Yangtze River Delta

Capital allocation at Chaoju is split between returning cash and a build-and-buy expansion pipeline. Roughly HK$533 million of the original 2021 IPO proceeds still sits undeployed, earmarked for two distinct growth programmes.

The first lever is consolidation inside northern China, where Chaoju already has the strongest regional brand. The Chinese eye-hospital category is fragmented across regional independents, many of them sub-scale and without the senior surgeon depth or 3A regulatory standing that Chaoju brings to acquisitions. Roll-up economics are favourable when the acquirer's brand lifts the target's pricing power post-integration.

The second lever is breaking into the wealthy Yangtze River Delta (长三角), the cluster around Shanghai, Suzhou and Hangzhou that contains the country's most price-insensitive refractive customers. The Delta is currently dominated by other chains. Chaoju entering with its 3A licences, senior surgeon roster and the IPO-proceeds war chest is a credible, capital-backed attempt to address the highest-value pocket of demand in China.

Both levers require execution rather than ambition, which is the right place for shareholder scepticism to live. But the optionality is genuinely funded, and that matters.

The MoatMap Scorecard: Q67 V81 M57, StockRank 99

Here is the Chaoju Eye Care MoatMap StockRank:

• Quality: 67/100. Solid. Recurring demographic demand, regulatory cornered resource, brand-led pricing in the cash-pay segment, net-cash balance sheet, mid-teens return-on-equity track record. The Quality factor is reading the moat without overstating it.
• Value: 81/100. Strong. The engine of the case. 8.5x trailing earnings, 0.6x book, ~9.5 percent yield, 1.6x EV/EBITDA, and a cash balance that almost equals the market cap. The Value factor is loud here because the numbers are loud.
• Momentum: 57/100. Neutral-to-positive. The drawdown from the 2021 IPO has stopped accelerating; momentum has stabilised while the dividend doubling and buyback cadence reinforce floor pricing.
• Composite StockRank: 99/100. Strong Buy on the composite. Value is doing most of the heavy lifting; Quality endorses the durability of the cash flows the Value factor is pricing.

This is the Quality-acceptable / Value-extreme profile that the factor framework is built to surface. We covered the academic foundations for that reading in our guide to factor investing.

The Question Worth Sitting With

Over a billion RMB sits in cash deposits and structured products, near the entire market capitalisation of the company. Every long thesis on Chaoju has to answer the same question honestly.

Is that a fortress balance sheet underwriting the dividend, or a sign management cannot find anything better to do with the cash?

The bull read says the cash is the moat made liquid. A 9.5 percent yield funded by real cash flow plus a balance sheet that could survive a multi-year demand slump is a structural margin of safety. Buybacks at 0.6x book are mechanically accretive. Meanwhile the HK$533 million IPO-proceeds tranche earmarked for the build-and-buy pipeline gives management a credible, funded path into the Yangtze River Delta. If even one of those growth levers compounds, the multiple normalises from 1.6x EV/EBITDA toward something resembling a healthy hospital chain, and the rerating dominates returns.

The bear read is that the cash is sitting in deposits because management cannot identify reinvestment opportunities that clear their hurdle rate. A business holding cash near its market cap, for years, is signalling either an extreme conservative stance or an absence of ideas. Either way the equity does not compound. The investor collects a fat dividend yield but the underlying business stagnates, the share price drifts, and the cash slowly returns to shareholders rather than being multiplied by reinvestment.

Both reads are defensible. The factor framework, with StockRank 99, is implicitly weighting the bull read heavily, because the Value factor cannot tell the difference between cheap-because-temporary and cheap-because-permanent. The market, by pricing the name at 0.6x book for four years running, is implicitly weighting the bear read heavily.

The capital-return cadence (dividend doubled, buybacks that actually cancel, payout near 90 percent) is the strongest piece of evidence on the bull side. Management returning cash aggressively is the opposite of management hoarding it. Whether the Yangtze River Delta build-out converts is the variable the next two years will resolve.

Companion Reading

Chaoju sits inside our growing Greater-China cash-rich compounder cluster with some natural neighbours:

• Plover Bay (1523.HK) for the broader shape of a Hong Kong-listed, founder-owned, cash-generative small-cap with optionality on top of a defensible base business.
• Azeus Systems (BBW.SI) for the question of what happens when management of a cash-rich franchise returns nearly all the cash. The Azeus case is the more extreme version (99 percent payout) of the same capital-return philosophy that Chaoju is operating under.
• CTOS Digital (5301.KL) for the contrasting shape: a Quality-led monopoly with a cross-border growth question, where the factor framework reads Sell while the insider buying reads Buy. Chaoju inverts that: the factor framework reads Strong Buy while the price action argues Sell.

The Bottom Line

Chaoju Eye Care is one of the cleanest examples in our catalog of a structurally protected, cash-rich, slow-growth franchise priced as if the operating business is worth almost nothing on top of the cash. The lifecycle demand is real. The 3A licence cornered resource is real. The 9.5 percent dividend and the share-cancelling buybacks are real. The cash balance near the entire market cap is real. The cross-cycle growth question lives in whether management can deploy the IPO-proceeds tranche into the Yangtze River Delta productively, or whether the cash just keeps recycling back to shareholders as dividends.

For investors considering Chaoju as a single-name position, our guide to reviewing your portfolio for weak spots is the right framework for sizing a high-Value / low-Momentum name where the central catalyst (cash deployment versus continued recycle) is qualitative rather than quantitative.

For the full breakdown including segment economics, the three-stage lifecycle conversion math, the cataract reimbursement schedule, the SMILE Pro mix-shift economics, the Yangtze River Delta build-and-buy pipeline, and the cash-deployment timeline, the Chaoju Eye Care Deep Dive is the place to go.

Disclosure: posts are opinion, not financial advice. The author may be long names covered on MoatMap.